We are live on ! Find out more
COYA icon

Coya Therapeutics

58 hedge funds and large institutions have $46M invested in Coya Therapeutics in 2025 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 19 increasing their positions, 4 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

375% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 4

314% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 7

70% more capital invested

Capital invested by funds: $27.1M → $46M (+$18.9M)

61% more funds holding

Funds holding: 3658 (+22)

9.51% more ownership

Funds ownership: 28.44%37.94% (+9.5%)

Holders
58
Holders Change
+22
Holders Change %
+61.11%
% of All Funds
0.7%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
29
Increased
19
Reduced
4
Closed
7
Calls
$56K
Puts
Net Calls
+$56K
Net Calls Change
+$56K

COYA Hedge Fund Activity: Q4 2025 in Review

58 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Coya Therapeutics (COYA) for Q4 2025, worth a combined $46M — up 70% from $27.1M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new COYA positions and 7 closed out — a net gain of 22 holders — while 19 added to existing stakes and 4 trimmed.

The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $4.86M. The largest seller was Dauntless Investment Group, exiting entirely with an estimated $872K sold.

  • 58 institutional investors held Coya Therapeutics (COYA) as of Q4 2025, up from 36 in Q3 2025.
  • Funds reported $46M of Coya Therapeutics stock for Q4 2025, up 70% quarter-over-quarter.
  • 29 funds opened new Coya Therapeutics positions in Q4 2025 and 7 closed out, a net change of +22 holders.
  • The largest Coya Therapeutics buyer in Q4 2025 was Alyeska Investment Group, an estimated $4.86M added.
  • The largest Coya Therapeutics seller in Q4 2025 was Dauntless Investment Group, an estimated $872K sold.

Based on aggregated 13F filings for Q4 2025.